Alcon—the eye-focused pharma spun out of Novartis—is handing over $550 million to buy out Neurotech Pharmaceuticals, its ...

As policies from the last two presidential administrations put heightened focus on drug affordability in the United States, a ...

In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...

Recruiting an industry veteran to steer the company through its darkest hour of growth pressures, CSL has hired GSK’s Deborah ...

Many direct-to-patient (DTP) programs have significantly affected access to medicines, a survey of U.S. | Many direct-to-patient programs have significantly affected access to medicines, a survey of U ...

With the win fleshed out, AZ and Amgen are now eyeing regulatory filings to carve out a potential third indication for ...

The FDA is codifying its regulations around mobile apps that go along with prescription drugs, offering a clearer framework ...

Veradermics is keeping pace in an already high-octane year.  | Topline results show the biotech's lead asset, VDPHL01, ...

Next-gen manufacturer Antheia is teaming up with the U.S. Department of War to build out its infrastructure and onshore the U.S. drug supply chain.  | The Department of War is allotting a conditional ...

Cosette Pharmaceuticals has achieved a corporate milestone, securing an FDA approval for a legacy Daiichi Sankyo drug in its ...

AbbVie has formed a multiyear deal with the McLaren Formula 1 team, signing up to raise awareness of immune-mediated diseases ...

Eli Lilly is betting on a pediatric expansion to give it’s IL-23p19 inhibitor Omvoh an edge in the fiercely competitive ...